US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...

Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.

Research on the role that genes play in psoriasis has led to targeted therapies to reduce symptoms and slow disease ...

Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.

Otulfi is approved for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active ...

“The heroes here tonight are not make-believe heroes from Marvel Comics, but real-life heroes who have made an impact on ...

plaque psoriasis Guttate psoriasis isn’t as common ... psoriasis if they have an autoimmune disorder like rheumatoid arthritis or are undergoing chemotherapy. Smoking tobacco also raises ...

Amgen (NASDAQ: AMGN) has partnered with multi-talented actress, producer and entrepreneur La La Anthony to share her personal ...

Thousand Oaks, California Friday, October 4, 2024, 14:00 Hrs [IST] ...

Reference ustekinumab was originally approved by the FDA in 2009. Wezlana (ustekinumab-auub) was approved last October.